Cited 21 times in
Erythropoietin protects myocardium against ischemia-reperfusion injury under moderate hyperglycemia.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽영란 | - |
dc.contributor.author | 신은정 | - |
dc.contributor.author | 심재광 | - |
dc.contributor.author | 전지혜 | - |
dc.date.accessioned | 2015-12-28T10:59:56Z | - |
dc.date.available | 2015-12-28T10:59:56Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138474 | - |
dc.description.abstract | Erythropoietin (EPO), an essential hormone for erythropoiesis, provides protection against myocardial ischemia/reperfusion (I/R) injury. Hyperglycemia during acute myocardial infarction aggravates organ damage and attenuates the efficacies of various protective measures. This study aimed to investigate the protective role of EPO against myocardial I/R injury under a clinically relevant moderate hyperglycemic condition and its associated mechanisms. Eighty-two Sprague-Dawley rats were randomly assigned to six groups: normoglycemia-Sham, normoglycemia-I/R-control-saline (IRC), normoglycemia-I/R-EPO (IRE), hyperglycemia-Sham, hyperglycemia-IRC, and hyperglycemia-IRE. The rats received 1.2 g/kg dextrose or same volume of normal saline depending on the group. I/R was induced by a 30 min period of ischemia followed by reperfusion for 4 h. For 1 h before I/R injury, intravenous 4000 IU/kg of EPO was administered. EPO pretreatment significantly reduced the number of apoptotic cells and the infarct size compared with those of the control groups. EPO increased GATA-4 phosphorylation and acetylation against I/R in hyperglycemic myocardium. It also enhanced ERK induced GATA-4 post-translational modifications such as increased GATA-4 phosphorylation and acetylation, and decreased GATA-4 ubiquitination following hypoxia-reoxygenation in H9c2 cells in hyperglycemic medium. Increased GATA-4 stability by EPO diminished I/R-related down-regulation of Bcl-2 and reduction of caspase-3 activities in hyperglycemic myocardium. In conclusion, EPO pretreatment before I/R injury conveyed significant myocardial protection under moderate hyperglycemic condition through mechanisms involved in reduction of caspase-3 activity and up-regulation of Bcl-2 in association with enhanced ERK-induced GATA-4 stability. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1~9 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acetylation | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Apoptosis | - |
dc.subject.MESH | Cardiotonic Agents/administration & dosage | - |
dc.subject.MESH | Cardiotonic Agents/metabolism | - |
dc.subject.MESH | Caspase 3/metabolism | - |
dc.subject.MESH | Cell Line | - |
dc.subject.MESH | Erythropoietin/administration & dosage* | - |
dc.subject.MESH | Erythropoietin/metabolism | - |
dc.subject.MESH | GATA4 Transcription Factor/metabolism | - |
dc.subject.MESH | Hyperglycemia/complications* | - |
dc.subject.MESH | Hyperglycemia/metabolism | - |
dc.subject.MESH | Hyperglycemia/pathology | - |
dc.subject.MESH | MAP Kinase Signaling System/drug effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Myocardial Reperfusion Injury/metabolism | - |
dc.subject.MESH | Myocardial Reperfusion Injury/pathology | - |
dc.subject.MESH | Myocardial Reperfusion Injury/prevention & control* | - |
dc.subject.MESH | Myocytes, Cardiac/drug effects | - |
dc.subject.MESH | Myocytes, Cardiac/metabolism | - |
dc.subject.MESH | Myocytes, Cardiac/pathology | - |
dc.subject.MESH | Phosphorylation | - |
dc.subject.MESH | Proto-Oncogene Proteins c-bcl-2/metabolism | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Ubiquitination | - |
dc.title | Erythropoietin protects myocardium against ischemia-reperfusion injury under moderate hyperglycemia. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anesthesiology (마취통증의학) | - |
dc.contributor.googleauthor | Ji Hae Jun | - |
dc.contributor.googleauthor | Na Hyung Jun | - |
dc.contributor.googleauthor | Jae Kwang Shim | - |
dc.contributor.googleauthor | Eun Jung Shin | - |
dc.contributor.googleauthor | Young Lan Kwak | - |
dc.identifier.doi | 10.1016/j.ejphar.2014.09.038 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00172 | - |
dc.contributor.localId | A02135 | - |
dc.contributor.localId | A02205 | - |
dc.contributor.localId | A03552 | - |
dc.relation.journalcode | J00842 | - |
dc.identifier.eissn | 1879-0712 | - |
dc.identifier.pmid | 25446919 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0014299914006943 | - |
dc.subject.keyword | Bcl-2 | - |
dc.subject.keyword | Cardioprotection | - |
dc.subject.keyword | Caspase-3 | - |
dc.subject.keyword | Erythropoietin | - |
dc.subject.keyword | GATA binding protein-4 | - |
dc.subject.keyword | Hyperglycemia | - |
dc.contributor.alternativeName | Kwak, Young Lan | - |
dc.contributor.alternativeName | Shin, Eun Jung | - |
dc.contributor.alternativeName | Shim, Jae Kwang | - |
dc.contributor.alternativeName | Jun, Ji Hae | - |
dc.contributor.affiliatedAuthor | Kwak, Young Lan | - |
dc.contributor.affiliatedAuthor | Shin, Eun Jung | - |
dc.contributor.affiliatedAuthor | Shim, Jae Kwang | - |
dc.contributor.affiliatedAuthor | Jun, Ji Hae | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 745 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PHARMACOLOGY, Vol.745 : 1-9, 2014 | - |
dc.identifier.rimsid | 45337 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.